Skip to main content
Top
Published in: Molecular Diagnosis & Therapy 2/2016

01-04-2016 | Short Communication

Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions

Authors: Corinne Inauen, Véronique Rüfenacht, Amit V. Pandey, Liyan Hu, Henk Blom, Jean-Marc Nuoffer, Johannes Häberle

Published in: Molecular Diagnosis & Therapy | Issue 2/2016

Login to get access

Abstract

Introduction

Cysteamine is used to treat cystinosis via the modification of cysteine residues substituting arginine in mutant proteins.

Objectives

We investigated the effect of cysteamine on mutant argininosuccinate lyase (ASL), the second most common defect in the urea cycle.

Methods

In an established mammalian expression system, 293T cell lysates were produced after transfection with all known cysteine for arginine mutations in the ASL gene (p.Arg94Cys, p.Arg95Cys, p.Arg168Cys, p.Arg379Cys, and p.Arg385Cys), allowing testing of the effect of cysteamine over 48 h in the culture medium as well as for 1 h immediately prior to the enzyme assay.

Results

Cysteamine at low concentrations showed no effect on 293T cell viability, ASL protein expression, or ASL activity when applied during cell culture. However, incubation of transfected cells with 0.05 mM cysteamine immediately before the enzyme assay resulted in increased ASL activity of p.Arg94Cys, p.Arg379Cys, and p.Arg385Cys by 64, 20, and 197 %, respectively, and this result was significant (p < 0.01). Cell lysates carrying p.Arg385Cys and treated with cysteamine recover enzyme activity that is similar to the untreated designed mutation p.Arg385Lys, providing circumstantial evidence for the assumed cysteamine-induced change of a cysteine to a lysine analogue.

Conclusion

Since 12 % of all known genotypes in ASL deficiency are affected by a cysteine for arginine mutation, we conclude that the potential of cysteamine or of related substances as remedy for this disease should be investigated further.
Appendix
Available only for authorised users
Literature
2.
go back to reference Häberle J, Shahbeck N, Ibrahim K, Schmitt B, Scheer I, O’Gorman R, et al. Glutamine supplementation in a child with inherited GS deficiency improves the clinical status and partially corrects the peripheral and central amino acid imbalance. Orphanet J Rare Dis. 2012;7:48. doi:10.1186/1750-1172-7-48.CrossRefPubMedPubMedCentral Häberle J, Shahbeck N, Ibrahim K, Schmitt B, Scheer I, O’Gorman R, et al. Glutamine supplementation in a child with inherited GS deficiency improves the clinical status and partially corrects the peripheral and central amino acid imbalance. Orphanet J Rare Dis. 2012;7:48. doi:10.​1186/​1750-1172-7-48.CrossRefPubMedPubMedCentral
5.
go back to reference Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257(5):2518–21.PubMed Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257(5):2518–21.PubMed
6.
go back to reference Aly AM, Arai M, Hoyer LW. Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine). J Clin Invest. 1992;89(5):1375–81. doi:10.1172/JCI115725.CrossRefPubMedPubMedCentral Aly AM, Arai M, Hoyer LW. Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine). J Clin Invest. 1992;89(5):1375–81. doi:10.​1172/​JCI115725.CrossRefPubMedPubMedCentral
7.
go back to reference Hoagland MB, Novelli GD. Biosynthesis of coenzyme A from phospho-pantetheine and of pantetheine from pantothenate. J Biol Chem. 1954;207(2):767–73.PubMed Hoagland MB, Novelli GD. Biosynthesis of coenzyme A from phospho-pantetheine and of pantetheine from pantothenate. J Biol Chem. 1954;207(2):767–73.PubMed
11.
go back to reference Pisoni RL, Thoene JG, Christensen HN. Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. Role in therapeutic cystine removal? J Biol Chem. 1985;260(8):4791–8.PubMed Pisoni RL, Thoene JG, Christensen HN. Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. Role in therapeutic cystine removal? J Biol Chem. 1985;260(8):4791–8.PubMed
13.
14.
go back to reference Hu L, Pandey AV, Balmer C, Eggimann S, Rüfenacht V, Nuoffer JM, et al. Unstable argininosuccinate lyase in variant forms of the urea cycle disorder argininosuccinic aciduria. J Inherit Metab Dis. 2015;38(5):815–27. doi:10.1007/s10545-014-9807-3.CrossRefPubMed Hu L, Pandey AV, Balmer C, Eggimann S, Rüfenacht V, Nuoffer JM, et al. Unstable argininosuccinate lyase in variant forms of the urea cycle disorder argininosuccinic aciduria. J Inherit Metab Dis. 2015;38(5):815–27. doi:10.​1007/​s10545-014-9807-3.CrossRefPubMed
15.
go back to reference Hu L, Pandey AV, Eggimann S, Rüfenacht V, Moslinger D, Nuoffer JM, et al. Understanding the role of argininosuccinate lyase transcript variants in the clinical and biochemical variability of the urea cycle disorder argininosuccinic aciduria. J Biol Chem. 2013;288(48):34599–611. doi:10.1074/jbc.M113.503128.CrossRefPubMedPubMedCentral Hu L, Pandey AV, Eggimann S, Rüfenacht V, Moslinger D, Nuoffer JM, et al. Understanding the role of argininosuccinate lyase transcript variants in the clinical and biochemical variability of the urea cycle disorder argininosuccinic aciduria. J Biol Chem. 2013;288(48):34599–611. doi:10.​1074/​jbc.​M113.​503128.CrossRefPubMedPubMedCentral
16.
go back to reference Engel K, Vuissoz JM, Eggimann S, Groux M, Berning C, Hu L, et al. Bacterial expression of mutant argininosuccinate lyase reveals imperfect correlation of in-vitro enzyme activity with clinical phenotype in argininosuccinic aciduria. J Inherit Metab Dis. 2012;35(1):133–40. doi:10.1007/s10545-011-9357-x.CrossRefPubMed Engel K, Vuissoz JM, Eggimann S, Groux M, Berning C, Hu L, et al. Bacterial expression of mutant argininosuccinate lyase reveals imperfect correlation of in-vitro enzyme activity with clinical phenotype in argininosuccinic aciduria. J Inherit Metab Dis. 2012;35(1):133–40. doi:10.​1007/​s10545-011-9357-x.CrossRefPubMed
17.
go back to reference Sampaleanu LM, Vallee F, Thompson GD, Howell PL. Three-dimensional structure of the argininosuccinate lyase frequently complementing allele Q286R. Biochemistry. 2001;40(51):15570–80.CrossRefPubMed Sampaleanu LM, Vallee F, Thompson GD, Howell PL. Three-dimensional structure of the argininosuccinate lyase frequently complementing allele Q286R. Biochemistry. 2001;40(51):15570–80.CrossRefPubMed
18.
go back to reference Turner MA, Simpson A, McInnes RR, Howell PL. Human argininosuccinate lyase: a structural basis for intragenic complementation. Proc Natl Acad Sci USA. 1997;94(17):9063–8.CrossRefPubMedPubMedCentral Turner MA, Simpson A, McInnes RR, Howell PL. Human argininosuccinate lyase: a structural basis for intragenic complementation. Proc Natl Acad Sci USA. 1997;94(17):9063–8.CrossRefPubMedPubMedCentral
19.
go back to reference Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins. 2004;57(4):678–83.CrossRefPubMed Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins. 2004;57(4):678–83.CrossRefPubMed
20.
go back to reference Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph. 1990;8(1):52–6, 29. Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph. 1990;8(1):52–6, 29.
23.
go back to reference Linnebank M, Tschiedel E, Häberle J, Linnebank A, Willenbring H, Kleijer WJ, et al. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene. Hum Genet. 2002;111(4–5):350–9. doi:10.1007/s00439-002-0793-4.CrossRefPubMed Linnebank M, Tschiedel E, Häberle J, Linnebank A, Willenbring H, Kleijer WJ, et al. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene. Hum Genet. 2002;111(4–5):350–9. doi:10.​1007/​s00439-002-0793-4.CrossRefPubMed
24.
go back to reference Kleijer WJ, Garritsen VH, Linnebank M, Mooyer P, Huijmans JG, Mustonen A, et al. Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J Inherit Metab Dis. 2002;25(5):399–410.CrossRefPubMed Kleijer WJ, Garritsen VH, Linnebank M, Mooyer P, Huijmans JG, Mustonen A, et al. Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J Inherit Metab Dis. 2002;25(5):399–410.CrossRefPubMed
25.
go back to reference Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet. 1988;78(2):151–5.CrossRefPubMed Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet. 1988;78(2):151–5.CrossRefPubMed
27.
go back to reference Brawer JR, Reichard G, Small L, Schipper HM. The origin and composition of peroxidase-positive granules in cysteamine-treated astrocytes in culture. Brain Res. 1994;633(1–2):9–20 (pii:0006-8993(94)91516-4).CrossRefPubMed Brawer JR, Reichard G, Small L, Schipper HM. The origin and composition of peroxidase-positive granules in cysteamine-treated astrocytes in culture. Brain Res. 1994;633(1–2):9–20 (pii:0006-8993(94)91516-4).CrossRefPubMed
28.
go back to reference Jezegou A, Llinares E, Anne C, Kieffer-Jaquinod S, O’Regan S, Aupetit J, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. Proc Natl Acad Sci USA. 2012;109(50):E3434–43. doi:10.1073/pnas.1211198109.CrossRefPubMedPubMedCentral Jezegou A, Llinares E, Anne C, Kieffer-Jaquinod S, O’Regan S, Aupetit J, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. Proc Natl Acad Sci USA. 2012;109(50):E3434–43. doi:10.​1073/​pnas.​1211198109.CrossRefPubMedPubMedCentral
30.
go back to reference Smolin LA, Clark KF, Thoene JG, Gahl WA, Schneider JA. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis. Pediatr Res. 1988;23(6):616–20. doi:10.1203/00006450-198806000-00018.CrossRefPubMed Smolin LA, Clark KF, Thoene JG, Gahl WA, Schneider JA. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis. Pediatr Res. 1988;23(6):616–20. doi:10.​1203/​00006450-198806000-00018.CrossRefPubMed
31.
go back to reference Hua Long L, Halliwell B. Oxidation and generation of hydrogen peroxide by thiol compounds in commonly used cell culture media. Biochem Biophys Res Commun. 2001;286(5):991–4. doi:10.1006/bbrc.2001.5514. Hua Long L, Halliwell B. Oxidation and generation of hydrogen peroxide by thiol compounds in commonly used cell culture media. Biochem Biophys Res Commun. 2001;286(5):991–4. doi:10.​1006/​bbrc.​2001.​5514.
32.
go back to reference Yudkoff M, Daikhin Y, Ye X, Wilson JM, Batshaw ML. In vivo measurement of ureagenesis with stable isotopes. J Inherit Metab Dis. 1998;21(Suppl 1):21–9.CrossRefPubMed Yudkoff M, Daikhin Y, Ye X, Wilson JM, Batshaw ML. In vivo measurement of ureagenesis with stable isotopes. J Inherit Metab Dis. 1998;21(Suppl 1):21–9.CrossRefPubMed
Metadata
Title
Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions
Authors
Corinne Inauen
Véronique Rüfenacht
Amit V. Pandey
Liyan Hu
Henk Blom
Jean-Marc Nuoffer
Johannes Häberle
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 2/2016
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-015-0182-z

Other articles of this Issue 2/2016

Molecular Diagnosis & Therapy 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.